| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 136.56 | 14.0% | 36.7% |
| Total Income | 136.56 | 14.0% | 36.7% |
| Expenditure | 144.62 | 10.4% | 27.1% |
| PBT | -16.50 | 3.7% | 2.4% |
| Net Profit | -16.50 | 3.0% | 2.4% |
| OPM | -5.90% | 3.46pp | 7.97pp |
| NPM | -12.09% | 2.11pp | 4.04pp |
| EPS | -0.14 | 6.7% | 22.2% |
The Oncology Institute Reports Q3 2025 Results, Increases 2025 Guidance
04 May 2026 · 4 May, 7:14 am
Summary
The Oncology Institute reported a 36.7% increase in consolidated revenue, reaching $136.6 million for Q3 2025 compared to $99.9 million in the same period last year. Gross profit increased by 31.7% to $18.9 million. The net loss was $16.5 million, slightly higher than the previous year's $16.1 million. The company has updated its full year revenue guidance to $495 to $505 million and anticipates Adjusted EBITDA of approximately $0 to $2 million in Q4 2025.
Key Highlights
- 1
The Oncology Institute's consolidated revenue of $136.6 million increased 36.7% compared to $99.9 million in Q3 2024.
- 2
Gross profit reached $18.9 million, reflecting a 31.7% increase from the previous year.
- 3
The company reported a net loss of $16.5 million, slightly higher than the $16.1 million net loss in the same quarter last year.
- 4
Adjusted EBITDA was $(3.5) million, an improvement compared to $(8.2) million in the prior year quarter.
- 5
The company updated its full year revenue guidance to $495 to $505 million.
- 6
The company expects Adjusted EBITDA of approximately $0 to $2 million in the fourth quarter of 2025.
- 7
Retail Pharmacy and Dispensary revenue contributed $75.9 million with a gross profit of $12.8 million in Q3.
Management Comments
Daniel Virnich
We had a solid third quarter across all lines of our business. Our Pharmacy business continues to set records, and our new delegated lives in Florida are ramping nicely with strong MLR performance. During the quarter, we made meaningful progress in leveraging AI to drive efficiencies in our operations and improve the patient experience. These were just some of the factors that allowed us to increase our full-year guidance and reaffirm our positive outlook for Q4 adjusted EBITDA. As a leader in oncology value-based care, it is important for us to not only raise the quality of care but also lower that cost of care. We believe we are well-positioned to achieve this goal, while simultaneously driving durable and sustainable growth.
Informational and educational content only. Not investment advice.